Quantum-Si (NASDAQ:QSI – Get Free Report) and Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk.
Analyst Ratings
This is a summary of recent ratings and price targets for Quantum-Si and Adaptive Biotechnologies, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Quantum-Si | 1 | 1 | 2 | 0 | 2.25 |
| Adaptive Biotechnologies | 1 | 1 | 6 | 0 | 2.62 |
Quantum-Si currently has a consensus target price of $2.50, suggesting a potential upside of 71.23%. Adaptive Biotechnologies has a consensus target price of $30.06, suggesting a potential upside of 12.85%. Given Quantum-Si’s higher possible upside, equities analysts clearly believe Quantum-Si is more favorable than Adaptive Biotechnologies.
Profitability
This table compares Quantum-Si and Adaptive Biotechnologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Quantum-Si | -6,138.26% | -47.12% | -43.18% |
| Adaptive Biotechnologies | -20.73% | -36.81% | -13.77% |
Volatility & Risk
Quantum-Si has a beta of 3.21, meaning that its share price is 221% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 2.09, meaning that its share price is 109% more volatile than the S&P 500.
Earnings & Valuation
This table compares Quantum-Si and Adaptive Biotechnologies”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Quantum-Si | $1.60 million | 199.11 | -$101.34 million | ($0.46) | -3.17 |
| Adaptive Biotechnologies | $276.98 million | 15.35 | -$59.50 million | ($0.41) | -64.98 |
Adaptive Biotechnologies has higher revenue and earnings than Quantum-Si. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Quantum-Si, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
39.9% of Quantum-Si shares are owned by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 22.0% of Quantum-Si shares are owned by company insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Adaptive Biotechnologies beats Quantum-Si on 9 of the 13 factors compared between the two stocks.
About Quantum-Si
Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company's platform is comprised of the Platinum NGPS instrument; the Platinum Analysis Software service; and reagent kits and semiconductor chips for use with its instruments. It is used in protein identification, protein variants, antibody characterization, biomarker identification, and post translational modification analysis applications. The company was founded in 2013 is headquartered in Branford, Connecticut.
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Receive News & Ratings for Quantum-Si Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quantum-Si and related companies with MarketBeat.com's FREE daily email newsletter.
